143 related articles for article (PubMed ID: 19577015)
1. Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G.
Palma AC; Abecasis AB; Vercauteren J; Carvalho AP; Cabanas J; Vandamme AM; Camacho RJ
Infect Genet Evol; 2010 Apr; 10(3):373-9. PubMed ID: 19577015
[TBL] [Abstract][Full Text] [Related]
2. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.
Gonzalez LM; Santos AF; Abecasis AB; Van Laethem K; Soares EA; Deforche K; Tanuri A; Camacho R; Vandamme AM; Soares MA
J Antimicrob Chemother; 2008 Jun; 61(6):1201-4. PubMed ID: 18356151
[TBL] [Abstract][Full Text] [Related]
3. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
Santos AF; Abecasis AB; Vandamme AM; Camacho RJ; Soares MA
J Antimicrob Chemother; 2009 Mar; 63(3):593-9. PubMed ID: 19136678
[TBL] [Abstract][Full Text] [Related]
4. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
5. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G.
Palma AC; Covens K; Snoeck J; Vandamme AM; Camacho RJ; Van Laethem K
J Antimicrob Chemother; 2012 May; 67(5):1075-9. PubMed ID: 22331593
[TBL] [Abstract][Full Text] [Related]
7. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
Torti C; Uccelli MC; Quiros-Roldan E; Gargiulo F; Tirelli V; Lapadula G; Regazzi M; Pierotti P; Tinelli C; De Luca A; Patroni A; Manca N; Carosi G
J Clin Virol; 2006 Apr; 35(4):414-9. PubMed ID: 16280255
[TBL] [Abstract][Full Text] [Related]
8. Genotypic resistance tests for the management of the HIV-infected patient with non-B viral isolates.
Visco-Comandini U; Balotta C
Scand J Infect Dis Suppl; 2003; 106():75-8. PubMed ID: 15000590
[TBL] [Abstract][Full Text] [Related]
9. The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.
Martinez-Cajas JL; Wainberg MA; Oliveira M; Asahchop EL; Doualla-Bell F; Lisovsky I; Moisi D; Mendelson E; Grossman Z; Brenner BG
J Antimicrob Chemother; 2012 Apr; 67(4):988-94. PubMed ID: 22315096
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.
Torti C; Quiros-Roldan E; Monno L; Patroni A; Saracino A; Angarano G; Tinelli C; Lo Caputo S; Tirelli V; Mazzotta F; Carosi G; ;
J Med Virol; 2004 Sep; 74(1):29-33. PubMed ID: 15258965
[TBL] [Abstract][Full Text] [Related]
11. Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.
Doualla-Bell F; Avalos A; Gaolathe T; Mine M; Gaseitsiwe S; Ndwapi N; Novitsky VA; Brenner B; Oliveira M; Moisi D; Moffat H; Thior I; Essex M; Wainberg MA
Antimicrob Agents Chemother; 2006 Jun; 50(6):2210-3. PubMed ID: 16723586
[TBL] [Abstract][Full Text] [Related]
12. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
Soares RO; Batista PR; Costa MG; Dardenne LE; Pascutti PG; Soares MA
J Mol Graph Model; 2010 Sep; 29(2):137-47. PubMed ID: 20541446
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 primary and secondary antiretroviral drug resistance and genetic diversity among pregnant women from central Brazil.
Cardoso LP; Pereira GA; Viegas AA; Schmaltz LE; Stefani MM
J Med Virol; 2010 Mar; 82(3):351-7. PubMed ID: 20087934
[TBL] [Abstract][Full Text] [Related]
14. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.
Nijhuis M; Wensing AM; Bierman WF; de Jong D; Kagan R; Fun A; Jaspers CA; Schurink KA; van Agtmael MA; Boucher CA
J Infect Dis; 2009 Sep; 200(5):698-709. PubMed ID: 19627247
[TBL] [Abstract][Full Text] [Related]
15. Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.
Svedhem V; Lindkvist A; Bergroth T; Knut L; Sönnerborg A
J Med Virol; 2005 Aug; 76(4):447-51. PubMed ID: 15977242
[TBL] [Abstract][Full Text] [Related]
16. Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment.
Kagan RM; Cheung PK; Huard TK; Lewinski MA
Antiviral Res; 2006 Aug; 71(1):42-52. PubMed ID: 16600392
[TBL] [Abstract][Full Text] [Related]
17. The HIV-1 protease substitution K55R: a protease-inhibitor-associated substitution involved in restoring viral replication.
Margerison ES; Maguire M; Pillay D; Cane P; Elston RC
J Antimicrob Chemother; 2008 Apr; 61(4):786-91. PubMed ID: 18252693
[TBL] [Abstract][Full Text] [Related]
18. [Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor].
Mouroux M; Bossi P; Yvon-Groussin A; Delaugerre C; Valantin MA; Tubiana R; Coutellier A; Bonmarchand M; Bricaire F; Katlama C; Agut H; Huraux JM; Calvez V
Pathol Biol (Paris); 1999 May; 47(5):549-52. PubMed ID: 10418038
[TBL] [Abstract][Full Text] [Related]
19. Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor.
Gianotti N; Tambussi G; Boeri E; Lazzarin A
J Biol Regul Homeost Agents; 2001; 15(2):166-9. PubMed ID: 11501975
[TBL] [Abstract][Full Text] [Related]
20. Drug resistance in non-subtype B HIV-1.
Kantor R; Katzenstein D
J Clin Virol; 2004 Mar; 29(3):152-9. PubMed ID: 14962783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]